AstraZeneca shares drop 5.5% as investors react to reported merger talks with Bristol Myers Squibb

AstraZeneca's share price slipped on Monday after Reuters reported that the company is in merger talks with Bristol Myers Squibb.

The potential combination would create a drugmaker valued at roughly $400 billion, placing it among the largest pharmaceutical groups worldwide.

Investors reacted negatively, pushing the stock down about 5.5% as they weighed the strategic and financial implications of such a deal.

The development was highlighted in a STAT+ Pharmalittle column, which tracks key industry movements.